Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Community Health (CYH) and Valneva (VALN)

Tipranks - Sat Feb 21, 5:40AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GHResearch Report), Community Health (CYHResearch Report) and Valneva (VALNResearch Report).

President's Day Sale - 70% Off

Guardant Health (GH)

BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health today and set a price target of $145.00. The company’s shares closed last Thursday at $106.38.

According to TipRanks.com, Massaro has 0 stars on 0-5 stars ranking scale with an average return of -4.0% and a 33.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $129.06, which is a 21.1% upside from current levels. In a report issued on February 17, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $120.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Community Health (CYH)

Wells Fargo analyst Stephen Baxter maintained a Sell rating on Community Health yesterday and set a price target of $2.00. The company’s shares closed last Thursday at $3.52.

According to TipRanks.com, Baxter is a 1-star analyst with an average return of -1.7% and a 41.9% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Medline, Inc. Class A. ;'>

Currently, the analyst consensus on Community Health is a Hold with an average price target of $3.63.

Valneva (VALN)

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Valneva, with a price target of $18.00. The company’s shares closed last Thursday at $10.49.

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 1.3% and a 40.2% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Connect Biopharma Holdings. ;'>

Currently, the analyst consensus on Valneva is a Moderate Buy with an average price target of $12.85.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.